- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|α-cyano-beta-hydroxy-β-methyl-N-(2, 5-dibromophenyl)propenamide | alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide|
|LFM-A13 is a potent, cell-permeable, reversible, substrate competitive, and specific inhibitor of Bruton's tyrosine kinase (BTK) . It was the first reported BTK-selective tyrosine kinase inhibitor and the first anti-leukemic agent targeting BTK. Investigated preclinically for B-cell non-Hodgkin's lymphoma [5-6].
Structurally LFM-A13 is an analogue of a metabolite of the antirheumatic drug leflunomide. The Mahajan et al. article also reports a three-dimensional homology model suggesting an energetically favorable position of LFM-A13 docked within BTK's catalytic site .
|GtoPdb PubChem SID||315661337|
|Search Google for chemical match using the InChIKey||UVSVTDVJQAJIFG-VURMDHGXSA-N|
|Search Google for chemicals with the same backbone||UVSVTDVJQAJIFG|
|Search UniChem for chemical match using the InChIKey||UVSVTDVJQAJIFG-VURMDHGXSA-N|
|Search UniChem for chemicals with the same backbone||UVSVTDVJQAJIFG|
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 1300